Active, Not Recruiting
Eparlitozoviril as Adjuvant Therapy for Resectable HCC With MVI
NCT07658105
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
- Locations
-
- Tianjin Medical University Cancer Institute and Hospital Tianjin, Tianjin Municipality, China